Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1

Digestive Diseases and Sciences

Volumn 51, Issue 6, 2006, Pages 1043-1046

  Lee, Jae Lyun ^a   Kim, Jin Young ^a   Ryu, Min Hee ^a   Kang, Hye Jin ^a   Chang, Heung Moon ^a   Kim, Tae Won ^a   Lee, Hyoungnam ^a   Park, Ji Hyun ^a   Kim, Hee Cheol ^a   Kim, Jung Sun ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Gastrointestinal stromal tumor; Imatinib; Neurofibromatosis

Indexed keywords

GENOMIC DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

AGED; ARTICLE; CAFE AU LAIT SPOT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA EXTRACTION; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LEUKOPENIA; MICROSCOPY; NEUROFIBROMATOSIS; PERIORBITAL EDEMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR VOLUME; WILD TYPE;

ABDOMINAL PAIN; AGED; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DNA; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; JEJUNAL NEOPLASMS; MUTATION; NEUROFIBROMATOSIS 1; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746462976     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-8003-1     Document Type: Article

References (18)

1. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004
2. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
3. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125-2131, 1997
4. Miettinen M, Lasota J: Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12, 2001
5. Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y, Shinomura Y, Matsuzawa Y: Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202:80-85, 2004
6. Kim TW, Lee H, Kang Y-K, Choe MS, Ryu M-H, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS: Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10:3076-3081, 2004
7. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
8. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575-578, 1988
9. Fuller CE, Williams GT: Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 19:1-11, 1991
10. Cheng SP, Huang MJ, Yang TL, Tzen CY, Liu CL, Liu TP, Hsiao SC: Neurofibromatosis with gastrointestinal stromal tumors: insights into the association. Dig Dis Sci 49:1165-1169, 2004
11. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843-849, 1990
12. Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH: Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33:314-323, 2001
13. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW: Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191:181-188, 2000
14. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121, 2001
15. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW: Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem 276:7240-7245, 2001
16. Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM: Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 5:189-195, 2000
17. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148, 1996
18. Ingram DA, Wenning MJ, Shannon K, Clapp DW: Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood 101:1984-1986, 2003